

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/167947 A3

(51) International Patent Classification:

A61K 47/64 (2017.01) A61P 35/00 (2006.01)
A61K 38/00 (2006.01) C07K 14/705 (2006.01)
A61K 39/00 (2006.01) C07K 14/725 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2023/014302

(22) International Filing Date:

01 March 2023 (01.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/315,529	01 March 2022 (01.03.2022)	US
63/330,120	12 April 2022 (12.04.2022)	US
63/353,896	21 June 2022 (21.06.2022)	US

(71) Applicant: **CROSSLINK THERAPEUTICS INC.**
[US/US]; 244 Pearl Street, Cambridge, Massachusetts
02139 (US).

(72) Inventors: **CHAPARRO, Rodolfo, J.**; c/o Crosslink Therapeutics Inc., 244 Pearl Street, Cambridge, Massachusetts
02139 (US). **SEIDEL, Ronald, D., III**; c/o Crosslink Therapeutics Inc., 244 Pearl Street, Cambridge, Massachusetts
02139 (US).

apeutics Inc., 244 Pearl Street, Cambridge, Massachusetts
02139 (US).

(74) Agent: **RICIGLIANO, Joseph, W.**; Hoffmann & Baron
LLP, 6900 Jericho Turnpike, Syosset, New York 11791
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ATP-DEPENDENT AGONISTS OF IMMUNE CELLS FUNCTION AS ANTICANCER AGENTS




FIG. 1

(57) Abstract: The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher level complexes (e.g., trimers, tetramers, etc.). The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cell and/or NK cells) that function to promote anti-tumor immune responses. The constructs may be employed as anticancer agents/therapeutics for the treatment of solid tumors that have elevated levels of ATP.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

07 December 2023 (07.12.2023)